These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16445120)

  • 1. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P; Sasaki J
    Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Japanese toxicogenomics project: application of toxicogenomics.
    Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
    Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
    Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicogenomics in biomarker discovery.
    Decristofaro MF; Daniels KK
    Methods Mol Biol; 2008; 460():185-94. PubMed ID: 18449488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of applying toxicogenomics to increase the efficiency of drug discovery.
    Barros SA
    Pharmacogenomics; 2005 Sep; 6(6):547-50. PubMed ID: 16142994
    [No Abstract]   [Full Text] [Related]  

  • 10. A decade of toxicogenomic research and its contribution to toxicological science.
    Chen M; Zhang M; Borlak J; Tong W
    Toxicol Sci; 2012 Dec; 130(2):217-28. PubMed ID: 22790972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of toxicogenomic data in risk assessment: a regulatory perspective.
    Chan VS; Theilade MD
    Clin Toxicol (Phila); 2005; 43(2):121-6. PubMed ID: 15822767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies.
    Mutlib A; Jiang P; Atherton J; Obert L; Kostrubsky S; Madore S; Nelson S
    Chem Res Toxicol; 2006 Oct; 19(10):1270-83. PubMed ID: 17040096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates.
    Foster WR; Chen SJ; He A; Truong A; Bhaskaran V; Nelson DM; Dambach DM; Lehman-McKeeman LD; Car BD
    Toxicol Pathol; 2007 Aug; 35(5):621-35. PubMed ID: 17654404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity.
    Merrick BA; Bruno ME
    Curr Opin Mol Ther; 2004 Dec; 6(6):600-7. PubMed ID: 15663324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scoring multiple toxicological endpoints using a toxicogenomic database.
    Kiyosawa N; Ando Y; Watanabe K; Niino N; Manabe S; Yamoto T
    Toxicol Lett; 2009 Jul; 188(2):91-7. PubMed ID: 19446240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of toxicogenomics in the development of safe, efficacious and novel anti-microbial therapies.
    Sabir JS; Abu-Zinadah OA; Bora RS; Ahmed MM; Saini KS
    Infect Disord Drug Targets; 2013 Jun; 13(3):206-14. PubMed ID: 24087896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine.
    Youns M; Hoheisel JD; Efferth T
    Planta Med; 2010 Dec; 76(17):2019-25. PubMed ID: 20957595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.